+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Host-Microbe Co-metabolism System in Health and Disease

  • Book

  • June 2025
  • Elsevier Science and Technology
  • ID: 6035923
Host-Microbe Co-metabolism System in Health and Disease is an easy-to-follow reference of research progress in host-microbiome co-metabolism system (HMMS) and how this frontier could imply a better understanding of health, disease, and the discovery of novel drugs. The book summarizes recent studies that are progressing to complete a panorama of the host-microbiome co-metabolism system (HMMS) in health and disease. It discusses how sophisticated bioanalytical tools, tractable model organisms, and artificial intelligence could be integrated to answer key biological questions related to HMMS in the broader context of human health and drug discovery.

Table of Contents

1. Introduction to HMMS
2. Metabolic machinery and pathways of the HMMS
3. Signaling Characteristics of the HMMS
4. Biological roles of the HMMS in health and disease
5. HMMS and drug efficacy and safety
6. HMMS and drug target discovery
7. Deciphering the targetome and signalome of HMMS signals
8. Future perspectives on HMMS in promoting human health and preventing disease

Authors

Xiao Zheng China Pharmaceutical University, China. Dr. Zheng Xiao is a professor and doctoral supervisor at China Pharmaceutical University. He is a candidate for the National High Level Youth Talent Program, and also serves as the Vice Chairman of the Analytical Pharmacology Youth Committee of the Chinese Pharmacological Society and the Youth Editorial Committee of the Chinese Journal of Natural Medicines. The main research focus of Dr.Zheng is on the study of host-microbe metabolism regulation of endogenous molecules for new targets/mechanisms for drug prevention and treatment. He has published multiple SCI papers as the first/corresponding author in internationally renowned academic journals. Haiping Hao China Pharmaceutical University, China. Hao Haiping, researcher and a doctoral supervisor. He has served as Director of "211 Project�Construction Office,Dean of School of Pharmacy,Dean of School of MengMudi.In August 2019, he served as vice president of China Pharmaceutical University,September 2022, served as president of China Pharmaceutical University.He is mainly engaged in metabolic regulation and target discovery / confirmation. He has won two second prizes of the National Science and Technology Progress Award and four first prizes of the Ministry and provincial level. He is the winner of the National Science Fund for Distinguished Young Scholars, the young and middle-aged chief scientist (the first level) of the '333' high-level talent training project in Jiangsu Province, the winner of the first Young Science and Technology Outstanding Contribution Award in Jiangsu Province, the secretary general of the pharmaceutical discipline evaluation group of the Academic Degrees Committee of the State Council, and a member of the National Pharmacopoeia Committee. At present, he is also the chairman of the Committee of Applied Pharmacology of the Chinese Pharmaceutical Association, the vice chairman of the Committee of Analytical Pharmacology of the Chinese Pharmacological Association, and the vice chairman of the Jiangsu Pharmacological Association; Editorial board members of SCI journals Brit J. Pharmacol, Acta Pharmaceut Sin B, Chin J. Nat Med, etc.